Notizia - Recent Pharma, Healthcare and Biotech Happenings

Positive Phase 2 data for Roche’s lymphoma ADC Roche’s antibody-drug conjugate for non-Hodgkin lymphoma polatuzumab has already received breakthrough designation from the USFDA and priority medicine status in the EU, and the expectations for the same are running pretty high. Phase 2 data presented by the company at the American Society of Hematology (ASH) annual meeting suggests that the drug is worth waiting for. Study results have shown that adding the CD79b-targeting ADC to a regimen based on Roche’s bendamustine and Rituxan (rituximab) improved the overall response rates from 15% to 40% in patients suffering from relapsed or refractory diffuse large B-cell lymphom...